Moderna, Inc.
MRNA Large CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Moderna, Inc. en bref
Moderna, Inc. (MRNA) is currently trading at 55,82 € with a market capitalization of 22,1 Md €. The 52-week range spans from 19,44 € to 59,12 €; the current price is 5.6% below the yearly high. Year-over-year revenue growth stands at +260.2%.
💰 Dividende
Moderna, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
20 analystes évaluent Moderna, Inc. (MRNA) au consensus : Conserver. L'objectif de cours moyen est de 37,79 €, soit un potentiel de -32.3% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 18,33 € à 60,21 €.
Moderna, Inc. : la thèse d'investissement en détail
Moderna, Inc. (MRNA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 260.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 17.82% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The share is trading at 91.7% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 260.2% sur un an
- Bilan solide avec faible endettement (D/E 17.52)
- –Actuellement non rentable
- –Positions vendeuses élevées (17.82%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (17.82%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Moderna, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news